Approximately 94% of hepatitis C patients who were prescribed direct-acting antiretrovirals (DAAs) were able to achieve the primary outcome goal, sustained virologic response (SVR), even though many patients had advanced liver disease, previous treatment failure, or previous liver transplants, according to a recent Walgreens Center for Health and Wellbeing Research study assessing a collaboration between Piedmont Healthcare's hepatitis C specialty clinic and a Walgreens local specialty pharmacy. "Collaboration between pharmacists and providers is key to optimizing patients’ response to treatment," said Shauna Markes-Wilson, study author and local specialty pharmacist for Walgreens. "Pharmacists provide high-touch support to overcome treatment challenges such as insurance prior-authorization and high copays. We ensure patient safety through drug interaction screening and patient education," she added. "We communicate regularly to ensure that patients are adherent to their care plans and address any side effects, while keeping our providers in the loop." The study, published in the Journal of the American Pharmacists Association, used a joint clinical and pharmacy database of patients who were prescribed DAAs. Outcomes assessed included time-to-therapy, SVR, insurance appeals, and copay assistance amount.